Search research articles
Contact Us
Filters
Showing results (191-200 of 483) with videos related to
Page
of 49
Sort By:
Plos One
|
August 31, 2011
Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells
Gabriele Brachtl, Karine Sahakyan, Ursula Denk, et al.
Frontiers in Neurology
|
March 20, 2026
Different types of electrostimulation target specific impaired sensory and motor functions in chemotherapy-induced peripheral neuropathy: a secondary analysis of a controlled trial
Florian Rieder, Robert Sassmann, Yvonne Theres Kienberger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)
Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Blood
|
February 7, 2014
Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells
Sebastian W Hofbauer, Peter W Krenn, Sylvia Ganghammer, et al.
Anticancer Research
|
December 27, 2011
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)
Ewald Wöll, Richard Greil, Wolfgang Eisterer, et al.
Haematologica
|
November 16, 2014
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr, et al.
International Journal of Molecular Sciences
|
July 2, 2021
Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia
Thomas Parigger, Franz Josef Gassner, Christian Scherhäufl, et al.
Clinical Therapeutics
|
May 31, 2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Victor Moreno, Richard Greil, Jeffrey Yachnin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 6, 2022
Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study
Ingo J Diel, Richard Greil, Jan Janssen, et al.
Blood
|
October 29, 2008
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig, Roman Hajek, Elena Tóthová, et al.
Page
of 49
Search research articles
Search
Showing results (191-200 of 483) with videos related to
Sort By:
Page
of 49
Plos One
|
August 31, 2011
Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells
Gabriele Brachtl, Karine Sahakyan, Ursula Denk, et al.
Frontiers in Neurology
|
March 20, 2026
Different types of electrostimulation target specific impaired sensory and motor functions in chemotherapy-induced peripheral neuropathy: a secondary analysis of a controlled trial
Florian Rieder, Robert Sassmann, Yvonne Theres Kienberger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)
Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Blood
|
February 7, 2014
Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells
Sebastian W Hofbauer, Peter W Krenn, Sylvia Ganghammer, et al.
Anticancer Research
|
December 27, 2011
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)
Ewald Wöll, Richard Greil, Wolfgang Eisterer, et al.
Haematologica
|
November 16, 2014
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr, et al.
International Journal of Molecular Sciences
|
July 2, 2021
Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia
Thomas Parigger, Franz Josef Gassner, Christian Scherhäufl, et al.
Clinical Therapeutics
|
May 31, 2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Victor Moreno, Richard Greil, Jeffrey Yachnin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 6, 2022
Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study
Ingo J Diel, Richard Greil, Jan Janssen, et al.
Blood
|
October 29, 2008
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig, Roman Hajek, Elena Tóthová, et al.
Page
of 49